At a Glance
| Feature | Detail |
|---|---|
| Condition | Crohn's Disease |
| ICD-10 Code | K50 |
| CDL Status | YES — Chronic Disease List |
| PMB Coverage | Full for csDMARDs and surgical management. Biologics require exceptional needs authorisation. |
| SA Prevalence | Rare but rising; estimated 5,000–15,000 SA patients (private sector) |
| Standard Treatment | Step-up: 5-ASA / budesonide → azathioprine → biologic |
| Annual Cost Range | R11,600 (mild) to R122,900 (biologic) |
| Biologic Risk | YES — anti-TNF, vedolizumab, ustekinumab |
| Key Advisory Angle | Biologic escalation + bowel surgery are the two major financial exposures. Surgery is not curative. |
About Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease (IBD) characterised by transmural (full-thickness) inflammation that can affect any part of the gastrointestinal tract from mouth to anus — most commonly the terminal ileum (end of the small bowel) and colon. Unlike ulcerative colitis, Crohn's is not curable with surgery: it can recur in previously unaffected bowel.
Crohn's is increasing in South Africa and sub-Saharan Africa, tracking global patterns of urbanisation, dietary change, and improved diagnostic access. It has historically been rare in Black African populations but this is changing. The condition is approximately equally distributed between sexes.
How Crohn's Disease Behaves
Crohn's follows a relapsing-remitting course. Disease complications include:
- Luminal disease: ongoing inflammation causing diarrhoea, cramping, and weight loss
- Stricturing disease: chronic inflammation causing bowel narrowing → obstruction
- Fistulising/penetrating disease: inflammation tracks through bowel wall to form fistulae (abnormal connections) to adjacent bowel, bladder, skin, or vagina; perianal fistulae are particularly burdensome
- Abscesses: collections of infection at fistula tracts — require surgical drainage
- Extra-intestinal manifestations: arthritis, uveitis (eye inflammation), erythema nodosum (skin), primary sclerosing cholangitis (liver)
Disease activity is measured using the Harvey-Bradshaw Index (HBI) or Crohn's Disease Activity Index (CDAI). CRP (C-reactive protein) and faecal calprotectin are the standard biomarkers for monitoring disease activity.
Treatment Pathway
Step 1 — Induction of Remission
- Mild–moderate ileocaecal Crohn's: Budesonide 9mg daily (locally-acting steroid, minimal systemic absorption) — 8–10 weeks course
- Moderate–severe disease: Systemic prednisolone 40–60mg daily — short-course induction only; not for maintenance. Aim to taper within 12 weeks.
- Perianal fistulae: Antibiotics (metronidazole + ciprofloxacin) as initial therapy, plus surgical seton placement to allow drainage while systemic therapy is optimised
Step 2 — Maintenance with Immunomodulators (csDMARDs)
Azathioprine (2–2.5mg/kg/day) or 6-mercaptopurine (6-MP) are the backbone steroid-sparing maintenance agents. TPMT enzyme testing is recommended before starting — a small proportion of patients have severely reduced TPMT activity and are at risk of myelosuppression at standard doses. Takes 3–6 months to reach full effect. Methotrexate (25mg weekly SC) is an alternative for patients intolerant of thiopurines, and has particular utility in patients with concurrent arthritis.
Regular monitoring is required: full blood count (FBC) and liver function tests (LFTs) monthly for the first 3 months, then 3-monthly once stable.
Step 3 — Biologic Therapy
For moderate-severe Crohn's failing ≥ 2 immunomodulator trials: - Anti-TNF agents (first biologic class): Adalimumab (SC, biosimilar AMGEVITA available — ~R5,000/month) or infliximab (IV, biosimilar CT-P13 available — ~R7,000/month). Combination with azathioprine improves efficacy and reduces immunogenicity. Pre-treatment screening for TB (QuantiFERON or Mantoux), hepatitis B, and HIV is mandatory before starting anti-TNF therapy. - Vedolizumab (Entyvio): Gut-selective anti-integrin; IV infusion; ~R14,000/month. Minimal systemic immunosuppression — preferred in patients with recurrent infections or older patients at higher infection risk. - Ustekinumab (Stelara): Anti-IL-12/23; IV induction then SC maintenance; ~R12,000/month. Often used as second-line biologic after anti-TNF failure.
Annual Cost Estimates (Private Sector)
| Severity | Profile | Estimated Annual Cost |
|---|---|---|
| Mild | Budesonide induction + 5-ASA maintenance | ~R11,600 |
| Moderate | Azathioprine + steroid courses + colonoscopy | ~R17,400 |
| Severe (biosimilar) | Adalimumab biosimilar + AZA | ~R74,900 |
| Severe (originator) | Adalimumab originator + AZA | ~R122,900 |
The PMB and CDL Position
All schemes must fund at CDL level: - Oral corticosteroids (induction), budesonide, 5-ASA agents - Immunomodulators (azathioprine, 6-MP, methotrexate) - Gastroenterologist consultations, colonoscopy - Bowel surgery (resection, abscess drainage, fistulectomy) as PMB
Biologics: NOT standard CDL formulary. Require gastroenterologist motivation and scheme exceptional needs authorisation. Biosimilar anti-TNF agents (adalimumab AMGEVITA, infliximab CT-P13) are available in SA and are significantly cheaper than originators.
Gap Cover Relevance
| Scenario | Gap Cover Relevance |
|---|---|
| csDMARD (AZA, MTX) management | LOW — CDL-funded |
| Biologic OOP cost | NONE — gap cover doesn't address formulary exclusions |
| Acute flare hospitalisation: gastro shortfall | HIGH |
| Bowel resection surgery: colorectal surgeon shortfall | VERY HIGH — R20,000–R50,000 shortfall potential |
| Abscess drainage or fistulectomy | HIGH |
| Colonoscopy + biopsies: proceduralist shortfall | MEDIUM |
The Talk to Eldon Angle
Two financial exposures define Crohn's disease management: biologic drug cost and surgical complication. csDMARDs (azathioprine R400/month) are CDL-funded and inexpensive. The biosimilar-originator adalimumab gap (~R48,000/year) mirrors RA. Separately, up to 50% of Crohn's patients require surgery within 10 years — colorectal surgeon shortfall on bowel resection is the major gap cover use case.
Unlike ulcerative colitis, surgery does not cure Crohn's. Plan for a long-term relationship with both your gastroenterologist and your scheme's biologic authorisation process.
Sources
- Emerging Patterns of IBD in Sub-Saharan Africa. J Crohn's Colitis, January 2025.
- Epidemiology, Natural History, and Treatment of IBD in Africa. Clin Gastroenterol Hepatol, 2025.
- CMS PMB Regulations — CDL: Crohn's Disease.
Ready to check your Crohn's cover? Run your AURA medical aid check